Rights and permissions
About this article
Cite this article
Costs for third-line gefitinib for NSCLC are acceptable. Inpharma Wkly. 1604, 17 (2007). https://doi.org/10.2165/00128413-200716040-00032
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200716040-00032